A "Head-to-Head" Scientific Comparative Study: YF Cryoprotectant Self-Developed by Yinfeng Life Science Research Institute Demonstrates Significantly Superior Safety and Ice Inhibition Efficacy
Release time:
2026-09-09
In the field of cryopreservation, cryoprotectants are often likened to "antifreeze" for cells. However, they must not only provide frost protection but also remain sufficiently "gentle" to the cells. Recently, the YF cryoprotectant, independently developed by Yinfeng Life Science Research Institute, underwent a rigorous parallel comparison with the M22 cryoprotectant used by other research institutions. The results showed that YF significantly outperformed M22 in both core metrics: safety and ice-inhibiting capacity.
Cell Viability: YF Achieves Near "Lossless" Protection, While M22 Causes Obvious Damage
Human umbilical cord mesenchymal stem cells (hUC-MSCs) were selected as the test subject. Post-treatment cell viability was measured as follows:
YF group: The average viability decreased by only 6.66% ± 1.23 compared to pre‑cryopreservation sample viability, with no statistically significant difference (P > 0.05). This indicates that the YF cryoprotectant offers remarkable protective effects, approaching "lossless" performance.
M22 group: The average viability dropped by 17.34% ± 5.52 relative to pre‑cryopreservation levels, with a highly significant statistical difference (P < 0.0001). This demonstrates a substantial gap in protective efficacy compared to YF.
Data consistency is equally critical—across repeated tests, the standard deviation for YF was only 1.23, reflecting high reproducibility across batches and operations; in contrast, M22 showed a standard deviation as high as 5.52, indicating considerable fluctuation. In the most extreme case, the lowest viability recorded for YF exceeded the lowest for M22 by a striking 20.46 percentage points. This means that choosing YF not only ensures near‑complete protection for the vast majority of cells but also delivers stable, reliable results—leaving nothing to chance.
Why is YF so "gentle"? Its formulation employs a combination of multiple permeable cryoprotectants to avoid the chemical shock associated with high concentrations of a single agent. Additionally, protective matrices are added to help regulate osmotic pressure, stabilize cell membranes, and mitigate oxidative stress. Importantly, no synthetic ice‑inhibiting agents are included, thereby circumventing the non‑specific cytotoxicity that such components might induce.
Figure: Effect of YF cryoprotectant versus M22 on hUC-MSC viability.
Ice Inhibition: YF Prevents Ice Crystals from "Growing Large," While M22 Fails to Block "Ice Spike Formation"
Another major cause of cryoinjury is ice crystals—as they grow and form sharp "ice spikes," these act like tiny blades that can puncture cell membranes and organelles, leading to damage. Thus, ice‑inhibiting capacity is a critical secondary indicator for evaluating cryoprotectant performance. Two experimental methods were employed to compare the suppression of ice crystal growth between YF and M22.
Method 1: Ice recrystallization inhibition assay (‑8°C annealing for 30 minutes)
Results showed that under identical concentrations and conditions, the average ice crystal area in the YF‑treated group was significantly smaller, indicating effective prevention of small crystals merging into larger ones. In contrast, the M22‑treated group exhibited substantially larger crystal areas and pronounced recrystallization—a clear threat to biological samples.
Method 2: Single‑ice‑crystal dynamic growth experiment (4 M concentration, 0–9.5 seconds)
Observing the temporal growth trajectory of ice crystals: in YF, both area and equivalent radius increased very slowly, remaining consistently small; whereas in M22, crystals grew rapidly in the later stage, forming large star‑shaped or dendritic structures with sharp edges that are highly prone to causing physical damage to cells.
Taken together, under identical conditions, YF demonstrates superior overall ice‑inhibiting performance compared to M22. The underlying mechanism is that YF more effectively disrupts the ordered arrangement of water molecules at the ice‑water interface, reducing water molecular mobility, thereby inhibiting ice nucleation and growth at the source.
From Follower to Runner‑Up: Domestically Produced Cryoprotectant Wins Recognition with Hard Data
Shandong Yinfeng Life Science Research Institute (hereinafter referred to as "Yinfeng Life Sciences") is a non‑profit research institution invested by Yinfeng Bioengineering Group and approved by the Shandong Provincial Department of Civil Affairs. It focuses on R&D and translation in gene technology, cell technology, cryomedicine, and regenerative medicine.
In the field of cryomedicine, Yinfeng Life Sciences has launched the "Yinfeng Life Extension Program," dedicated to tackling the challenges of cryopreservation and rewarming of tissues, organs, and even large‑sized intact organisms. The team brings together multidisciplinary experts in cryobiomedicine, clinical medicine, regenerative medicine, artificial intelligence, law, and ethics. To date, it has independently developed over 30 variants of the YF series of cryoprotectants covering cells, tissues, and organs, among which the protectant for large‑sized biological specimens has been upgraded to version 3.0.
This head‑to‑head comparative study, backed by solid and transparent data, unequivocally demonstrates that China‑developed cryoprotectants already possess significant international competitiveness in core performance. This not only reflects Yinfeng's technological prowess but also serves as a compelling testament to China's cryobiomedicine field transitioning from "following" to "running alongside" global leaders—earning international discourse power through scientific evidence.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
